226 related articles for article (PubMed ID: 23152009)
1. [Managing cutaneous toxicities of targeted therapies].
Kiyohara Y
Gan To Kagaku Ryoho; 2012 Nov; 39(11):1597-602. PubMed ID: 23152009
[TBL] [Abstract][Full Text] [Related]
2. Advances in the management of cutaneous toxicities of targeted therapies.
Robert C; Sibaud V; Mateus C; Cherpelis BS
Semin Oncol; 2012 Apr; 39(2):227-40. PubMed ID: 22484194
[TBL] [Abstract][Full Text] [Related]
3. [Management of adverse effects of targeted therapy toxicities in oncology].
Coquan E; Henri P; de Raucourt S; Lireux B; Lamy E; Delcambre C; Sevin E; Dutriaux C; Bouhier-Leporrier K; Gervais R; Joly F
Rev Prat; 2012 Jan; 62(1):17-25. PubMed ID: 22335060
[TBL] [Abstract][Full Text] [Related]
4. Skin care for cancer patients.
Lacouture ME
Clin Adv Hematol Oncol; 2012 Nov; 10(11):748-50. PubMed ID: 23271263
[No Abstract] [Full Text] [Related]
5. Side effects of targeted therapies: rash.
Eaby-Sandy B; Lynch K
Semin Oncol Nurs; 2014 Aug; 30(3):147-54. PubMed ID: 25085026
[TBL] [Abstract][Full Text] [Related]
6. Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents.
Borovicka JH; Calahan C; Gandhi M; Abraham TS; Kwasny MJ; Haley AC; West DP; Lacouture ME
Arch Dermatol; 2011 Dec; 147(12):1403-9. PubMed ID: 22184762
[TBL] [Abstract][Full Text] [Related]
7. Targeted agents: management of dermatologic toxicities.
Burtness B
J Natl Compr Canc Netw; 2014 May; 12(5 Suppl):793-6. PubMed ID: 24853219
[TBL] [Abstract][Full Text] [Related]
8. Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer.
Tang N; Ratner D
Dermatol Surg; 2016 Jan; 42 Suppl 1():S40-8. PubMed ID: 26730973
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy and cutaneous toxicities: implications for oncology nurses.
Viale PH
Semin Oncol Nurs; 2006 Aug; 22(3):144-51. PubMed ID: 16893743
[TBL] [Abstract][Full Text] [Related]
10. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
Edmonds K; Hull D; Spencer-Shaw A; Koldenhof J; Chrysou M; Boers-Doets C; Molassiotis A
Eur J Oncol Nurs; 2012 Apr; 16(2):172-84. PubMed ID: 21641280
[TBL] [Abstract][Full Text] [Related]
11. Skin Manifestations of Targeted Antineoplastic Therapy.
Sanmartín O
Curr Probl Dermatol; 2018; 53():93-104. PubMed ID: 29131041
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous reactions to chemotherapy: commonly seen, less described, little understood.
Sanborn RE; Sauer DA
Dermatol Clin; 2008 Jan; 26(1):103-19, ix. PubMed ID: 18023774
[TBL] [Abstract][Full Text] [Related]
13. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.
Boone SL; Rademaker A; Liu D; Pfeiffer C; Mauro DJ; Lacouture ME
Oncology; 2007; 72(3-4):152-9. PubMed ID: 18160805
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy.
Reyes-Habito CM; Roh EK
J Am Acad Dermatol; 2014 Aug; 71(2):217.e1-217.e11; quiz 227-8. PubMed ID: 25037801
[TBL] [Abstract][Full Text] [Related]
15. [Skin toxicity].
Sato A; Hamada K; Imataka H
Gan To Kagaku Ryoho; 2011 Nov; 38(11):1767-72. PubMed ID: 22083182
[TBL] [Abstract][Full Text] [Related]
16. Psychosocial impact of cutaneous toxicities associated with epidermal growth factor receptor-inhibitor treatment.
White KJ; Roydhouse JK; Scott K
Clin J Oncol Nurs; 2011 Feb; 15(1):88-96. PubMed ID: 21278044
[TBL] [Abstract][Full Text] [Related]
17. Non-rash skin toxicities associated with novel targeted therapies.
Lacouture ME; Boerner SA; Lorusso PM
Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S36-42. PubMed ID: 17239289
[TBL] [Abstract][Full Text] [Related]
18. [Skin toxicity, alopecia].
Katsura Y; Akatsuka S; Toda Y; Arioka H
Nihon Rinsho; 2012 Aug; 70 Suppl 6():166-71. PubMed ID: 23156503
[No Abstract] [Full Text] [Related]
19. Ocular toxicity of targeted therapies.
Renouf DJ; Velazquez-Martin JP; Simpson R; Siu LL; Bedard PL
J Clin Oncol; 2012 Sep; 30(26):3277-86. PubMed ID: 22649132
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of dermatological toxicities associated with sorafenib.
Zhang L; Zhou Q; Ma L; Wu Z; Wang Y
Clin Exp Dermatol; 2011 Jun; 36(4):344-50. PubMed ID: 21507035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
